| Name | Title | Contact Details |
|---|
KeySource Medical, Inc. (KMI) has been supplying the generic pharmaceutical needs of retail pharmacies across the United States since 1996. Our sales force is focused on serving the interests of our customers, emphasizing the highest level of service, integrity and value. As a trusted wholesale distributor of generic pharmaceuticals, we take our responsibility to safeguard the integrity of the pharmaceutical supply chain seriously, securing it against counterfeit or adulterated products. • KeySource purchases ALL products it sells directly from FDA approved manufacturers. • KeySource has received VAWD (Verified-Accredited Wholesale Distributor) accreditation from the National Association of Boards of Pharmacy. • KeySource is an active member of HDMA (Healthcare Distribution Management Association), a National Association comprised of America`s largest pharmaceutical distributors KMI has been recognized by “INC. Magazine” as one of America`s fastest growing, privately-held companies, placing #162 on the “INC. 500” list in 2006. In 2009, KMI was a finalist and category winner in the “Fast 55” competition sponsored by the Cincinnati Business Courier. KeySource Medical is committed to serving the community through the Dennis J. Engel Giving Program. We help make it possible to serve the uninsured and those in need with prescriptions at no cost through The St. Vincent de Paul Charitable Pharmacy.
Reata Pharmaceuticals is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes.
Gnosko Bio is a medical and laboratory supply company based in Philadelphia, PA that provides real-time inventory management automation solutions for the biotech industry.
EYEVANCE Pharmaceuticals` mission is to develop and commercialize INNOVATIVE and IMPACTFUL ophthalmic products to enable optimal vision and better quality of life for all patients
Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.